Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence

A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years

(2014) Hideko Nakahara et al.   Modern Rheumatology

Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome

(2014) Masafumi Kobayashi et al.   Modern Rheumatology

Successful tocilizumab treatment in a patient with adult-onset Still’s disease complicated by chronic active hepatitis B and amyloid A amyloidosis

(2014) Dai Kishida et al.   Modern Rheumatology

Successful treatment of adult-onset Still’s disease with tocilizumab monotherapy: two case reports and literature review

(2012) Ryota Sakai et al.   CLINICAL RHEUMATOLOGY

Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6

(2012) Masaki Shimizu et al.   CYTOKINE

Eficacia de tocilizumab en la enfermedad de Still del adulto

(2012) Rosario López Buitrago et al.   MEDICINA CLINICA

Tocilizumab Improved both Clinical and Laboratory Manifestations Except for Interleukin-18 in a Case of Multiple Drug-Resistant Adult-Onset Still's Disease

(2011) Yoshihiro Yoshida et al.   INTERNAL MEDICINE

Les antagonistes de l’interleukine-6 (tocilizumab) dans la maladie de still réfractaire de l’adulte

(2011) Youssef Sekkach et al.   PRESSE MEDICALE

Treatment of refractory adult-onset still’s disease with tocilizumab: report of two cases and review of the literature

(2011) Rene Thonhofer et al.   RHEUMATOLOGY INTERNATIONAL

Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade

(2010) J. Rech et al.   ANNALS OF THE RHEUMATIC DISEASES

Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab

(2010) Keiichi Sumida et al.   CLINICAL RHEUMATOLOGY

A case of refractory adult-onset Still’s disease successfully controlled with tocilizumab and a review of the literature

(2010) Katja Perdan-Pirkmajer et al.   CLINICAL RHEUMATOLOGY

Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still’s disease

(2010) Taio Naniwa et al.   CLINICAL RHEUMATOLOGY

Clinical value of blocking IL-6 receptor

(2010) Toru Mima et al.   CURRENT OPINION IN RHEUMATOLOGY

The effect of tocilizumab on the uptake of 18FDG-PET imaging in patients with adult-onset Still's disease

(2010) M. L. Cunha et al.   RHEUMATOLOGY

Tocilizumab in Refractory Adult-Onset Still's Disease with Aseptic Meningitis—Efficacy of Interleukin-6 Blockade and Review of the Literature

(2010) Girish R. Sabnis et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Tocilizumab in refractory adult Still's disease

(2010) Xavier Puéchal et al.   ARTHRITIS CARE & RESEARCH

Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab

(2009) Kazuko Matsumoto et al.   CLINICAL RHEUMATOLOGY

Tocilizumab for multirefractory adult-onset Still's disease

(2008) M De Bandt et al.   ANNALS OF THE RHEUMATIC DISEASES

Adult-onset Still disease

(2008) Bruno Fautrel   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

(2008) Shumpei Yokota et al.   LANCET